Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 74

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 74
---
 | “At the market” offering that may be made from time to time through our Sales Agent, Cantor. See “Plan of 
 Distribution.”                                                                                            |

| Use of Proceeds | We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund our pipeline 
 development, to maintain our working capital, and for general corporate purposes.                                                |

| Listing | The Ordinary Shares are listed on the Nasdaq Global Market under the symbol “CNTB”. |

| Risk Factors | Before deciding to invest in the Ordinary Shares, you should carefully consider the risks related to our business, the offering and our                    
 securities. See “Risk Factors” on page 13 of this prospectus and under similar headings in other documents incorporated by reference into this prospectus. |

12

RISK FACTORS

Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described below and under the section titled “Risk Factors” in our most recent Annual Report on Form 10-Kand any subsequent Annual Report on Form 10-K,Quarterly Reports on Form 10-Qor Current Reports on Form 8-Kwe file after the date of this prospectus, and all other information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act, before acquiring any of such securities. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.

Risks Related to the Offering

We will have broad discretion in how to use the net proceeds of this offering, and we may not use these proceeds in a manner desired by our investors.

We will have broad discretion as to the use of the net proceeds from this offering and could use them for purposes
other than those contemplated at the time of this offering. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity as part of your investment decision to
assess whether the proceeds are being used appropriately. Our needs may change as the business and the industry that we address evolves. As a result, the proceeds to be received in this offering may be used in a manner significantly different from
our current expectations. It is possible that the proceeds will be invested in a way that does not yield a favorable, or any, return. The failure of our management to use such funds effectively could have a material adverse effect on our business,
financial condition, operating results and